Matching trials
2,411 results
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).
- Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Doxorubicin and Avastin® in Sarcoma.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Doxorubicin and Avastin® in Sarcoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00755261).
- Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05068752).
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01827371).
- Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02329730).
- Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).
- Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02217709).
- PHERGainIndependent statistical analysis of the phase 2 PHERGain trial evaluating a response-adapted strategy of trastuzumab and pertuzumab in HER2-positive breast cancer, including trial design, endpoints, planned statistical methods, and interpretation.
- Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura: Complete Statistical AnalysisIndependent statistical analysis of Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages: Complete Statistical AnalysisIndependent statistical analysis of Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PHranceSCaIndependent statistical analysis of A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer: primary endpoint…
- PIIPPIIndependent statistical analysis of COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04364802).
- Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds: Complete Statistical AnalysisIndependent statistical analysis of Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting: primary endpoint results, effect estimate with confidence interval,…
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Pilot Study of Duloxetine in Psychological Resilience: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Duloxetine in Psychological Resilience: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00331799).
- Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pilot Study of X-82 in Patients With Wet AMD: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of X-82 in Patients With Wet AMD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01674569).
- Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00215137).
- Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pilot Trial of “Chemo-Switch” Regimen to Treat Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00673361).
- Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: Complete Statistical AnalysisIndependent statistical analysis of Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PinPointe FootLaser for the Treatment of Onychomycosis: Complete Statistical AnalysisIndependent statistical analysis of PinPointe FootLaser for the Treatment of Onychomycosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00935649).
- Pioglitazone to Treat Fatty Liver in People With HIV Infection: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone to Treat Fatty Liver in People With HIV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00441272).
- Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PIONEERIndependent statistical analysis of the phase 2 PIONEER trial of CHF6001 in chronic obstructive pulmonary disease, including trial design, the primary FEV1 endpoint, planned statistical analysis, and interpretation.
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months: Complete Statistical AnalysisIndependent statistical analysis of Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to